|
| |
Argos TherapeuticsArgos Therapeutics, incorporated in 1997 and operated under the name Merix Bioscience prior to late 2004, traces its roots to Duke University, where company founders developed a unique RNA-based vaccine technology. In 2000, we completed our initial round of venture financing and acquired from Duke an exclusive worldwide license to the technology. The following year, the company closed a second venture round and acquired from Rockefeller University and Dr. Gerold Schuler's exclusive worldwide rights to complementary technology relating to the generation of dendritic cells (DCs), setting the stage for our current therapeutic development.
| Contact Details: |
| 4233 Technology Drive |
| Durham |
| North Carolina |
| 27704 |
| United States of America |
| Tel: | (919) 287-6300 |
| Fax: | |
| Email: | |
| WWW: | www.argostherapeutics.com/
|
|
Loading...
|
Recent Publications by Argos Therapeutics: |  |
Priming of a novel subset of CD28+ rapidly expanding high-avidity effector memory CTL by post maturation electroporation-CD40L dendritic cells is IL-12 dependent.
Dendritic cell (DC)-based immunotherapeutics must induce robust CTL... | 4th October, 2008
| Research Department, Argos Therapeutics, Inc, Durham, NC 27704, USA.
| J Immunol. 2008 Oct 15;181(8):5296-305.
|
Cytokine maturation followed by CD40L mRNA electroporation results in a clinically relevant dendritic cell product capable of inducing a potent proinflammatory CTL response.
Dendritic cells (DC) for the immunotherapy of cancer and infectious... | 10th September, 2008
| Research Department, Argos Therapeutics Inc, Durham, NC 27704, USA.
| J Immunother. 2008 Oct;31(8):731-41.
DOI Direct Link |
Multiplex RT-PCR amplification of HIV genes to create a completely autologous DC-based immunotherapy for the treatment of HIV infection.
BACKGROUND: Effective therapy for HIV-infected individuals remains an... | 9th August, 2008
| Research and Development Department, Argos Therapeutics, Inc., Durham,
| PLoS ONE. 2008 Jan 30;3(1):e1489.
DOI Direct Link |
Lessons from randomized phase III studies with active cancer immunotherapies--outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC).
After years of effort to develop active cancer immunotherapies, seven... | 17th January, 2008
| Argos Therapeutics,
| Vaccine. 2007 Sep 27;25 Suppl 2:B97-B109.
DOI Direct Link |
Dendritic cells for active immunotherapy: optimizing design and manufacture in order to develop commercially and clinically viable products.
Dendritic cell (DC) active immunotherapy is potentially efficacious in a... | 17th January, 2008
| Argos Therapeutics, 4233 Technology Drive, Durham, NC, United States.
| Vaccine. 2007 Sep 27;25 Suppl 2:B47-60. Epub 2007 Jun 21.
DOI Direct Link |
→View more Argos Therapeutics research publications. |
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 101 times since April 2007, the link to the organisation's website has been followed 14 times Recent Search Terms used to find this page: argos therapeutics North Carolina | t | . Search for more companies in Durham Search for more companies in North Carolina This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Argos Therapeutics |
